Health News

Merck KGaA announced that the Australian Therapeutic Goods Administration (TGA) has approved Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS)(1). Cladribine Tablets will be registered in Australia under the trade name Movectro®…

Read more

Filed under: Pharmacy News
Tags: Pharmacy, sclerosis

Related posts

• XenoPort to present XP23829 preclinical data at ECTRIMS meeting (0)
  XenoPort, Inc. announced today that it will present data on a new preclinical product candidate, XP23829, at the upcoming 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Gothenburg, Sweden, October 13 - 16, 2010. Read more [tags] Pharmacy News [/tags]
  
  
• XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis (0)
  XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients. Read more [tags] Pharmacy News [/tags]
  
  
• When Managed By Specialty Pharmacy, MS Patients More Compliant With Medications (0)
  Multiple sclerosis patients managed by a specialty pharmacy program were more compliant with medication, and had a lower risk of being hospitalized for their disease than those who were not managed by a specialty pharmacy program, according to a study completed by HealthCore, Inc. HealthCore researcher Jingbo Yu presented the study at [...]
  
  
• Viagra helps reduce clinical signs of multiple sclerosis (0)
  Universitat Autònoma de Barcelona researchers have discovered that Viagra drastically reduces multiple sclerosis symptoms in animal models with the disease. The research, published in Acta Neuropathologica, demonstrates that a practically complete recovery occurs in 50% of the animals after eight days of treatment. Read more [tags] Pharmacy News [/tags]
  
  
• VBL Therapeutics’ VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment (0)
  VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis. Read [...]